跳至主要内容
临床试验/NCT01381471
NCT01381471已完成不适用

Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)

GlaxoSmithKline0 个研究点目标入组 11,060 人开始时间: 2009年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
11,060
主要终点
Mean Number of Pharmacy Claims by Participants During the Post-Index Period

研究概览

简要总结

The specific aim of this study is to describe 1 year Advair dispensing rates for patients with COPD, and to measure the association between Advair adherence and healthcare utilization (e.g. emergency room visits and inpatient admissions, etc.). To compare the risk of a COPD exacerbation (moderate or severe) during a 3-month follow-up period between patients thqat are adherent versus those that are not.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

COPD

Patients with a diagnosis code of COPD

干预措施: fluticasone propionate/salmeterol xinafoate combination (Drug)

结局指标

主要结局

Mean Number of Pharmacy Claims by Participants During the Post-Index Period

时间窗: One Year

The mean number of pharmacy claims incurred by participants during the one-year post-index period was measured.

Mean Number of Healthcare Encounters Incurred by Participants During the Post-Index Period

时间窗: One Year

The mean number of outpatient office visits, inpatient visits, and emergency department visits incurred by participants during the one-year post-index period was measured.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验